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REVIEW
rnA-based Gene therapy for the treatment
and Prevention of HiV: From Bench to Bedside
Skye J. Zeller and Priti Kumar*
Department of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine,
New Haven, Connecticut
Gene therapy is considered a feasible approach for the treatment and prevention of
HIV/AIDS. Targeting both viral genes and host dependency factors can interfere with the viral
lifecycle and prevent viral replication. A number of approaches have been taken to target
these genes, including ribozymes, aptamers, and RNAi based therapies. A number of these
therapies are now beginning to make their way into clinical trials and providing proof of prin-
ciple that gene therapy is a safe and realistic option for treating HIV. Here, we focus on
those therapies that have progressed along the pipeline to preclinical and clinical testing. 
introduction
Highly Active Antiretroviral Therapy
(HAART†) has been extremely effective in
controlling the disease progression kinetics
in HIV-infected individuals. The prohibi-
tive costs of the HAART regimen restrict-
ing  its  widespread  use  in  developing
countries, the associated side effects lead-
ing to non-compliance, and thus the devel-
opment of drug-resistant viral strains have
contributed to the current alarming num-
bers of 34 million HIV-infected individuals
worldwide [1]. This underscores the im-
portance  of  developing  an  effective  ap-
proach  that  can  either  prevent  viral
infection upon exposure or transmission
from infected individuals. In this review,
we will focus on RNA-based genetic ther-
apies that have been evaluated in a clinical
setting.  These  drugs  fall  into  two  cate-
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Both approaches have advantages and dis-
advantages. siRNA relies on host machinery
to be guided to its target, where ribozymes
or aptamers interact with target RNA via dif-
fusion [2]. However, RNAi can saturate en-
dogenous  processing  machinery  or  elicit
off-target effects leading to dysregulation of
host cells.  
The HIV lifecycle begins as it infects a
new host cell (Figure 1). HIV gp120 binds
to CD4 receptor, causing a conformational
change in gp120 and allowing binding to a
co-receptor, either CCR5 or CXCR4. Bind-
ing to a co-receptor causes fusion of the
viral envelope with the target cell mem-
brane, resulting in viral uncoating and ex-
posure of the dimeric RNA genome. This
genome is then reverse transcribed into dou-
ble-stranded DNA by viral reverse tran-
scriptase  (RT)  and  imported  into  the
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Figure 1. the lifecycle of HiV. HIV first binds to the cell via gp120 recognizing CD4 on
the host cell. This causes a conformational change that exposes the co-receptor binding
loop of gp120 and allows it to bind to co-receptor CCR5 or CXCR4. This causes fusion of
the viral envelope with the host cell membrane and leads to viral uncoating and reverse
transcription. The DNA is imported into the nucleus and integrated into the host cell’s
genome, where it can then undergo transcription and translation using host cell machin-
ery. New virions are assembled at the host cell membrane, where they are released by
budding. For gene therapy approaches, we can either target host dependency factors uti-
lized by the virus to complete this lifecycle or we can target viral genes. siRNA and ri-
bozymes can target the viral RNA during uncoating and following transcription, leading to
degradation of the RNA. Antisense oligonucleotides bind viral RNA after transcription, pre-
venting translation. Aptamers serve as RNA decoys that can bind the viral proteins, pre-
venting them from carrying out their function in the viral lifecycle. Single squiggly lines
represent RNA, double helix represents DNA, and circles represent viral proteins.  nucleus,  where  integration  occurs  using
viral  integrase.  Replication  of  the  viral
genome is divided into two phases, the first
of which includes multiply spliced tran-
scripts encoding rev and tat. These regula-
tory proteins are then re-imported into the
nucleus, where tat drives more viral tran-
scription and rev escorts singly spliced and
unspliced transcripts out of the nucleus to
make the proteins of late phase replication.
These proteins assemble at the host cell
membrane  in  virions  that  are  released
through budding. Once released from the
cell,  viral  protease  continues  to  cleave
polyproteins into the mature form, creating
infectious virus. This life cycle of HIV is
dependent on both viral and cellular factors
that when disrupted may impact viral repli-
cation. Viral targets present a unique and
distinct factor that should have little impact
on host cell function. However, the high
mutation  rate  of  HIV  and  the  relatively
small changes required to escape inhibition
may lead to the emergence of escape mu-
tants. Targeting the more immutable cellular
factors  (e.g.,  CCR5)  provides  a  lower
chance of mutation, but long-term inhibi-
tion of cellular factors may lead to deleteri-
ous effects in host cells. Presented in this
review are the approaches that have been
taken to target these genes in clinical stud-
ies by RNA-based genetic therapies, in-
cluding ribozymes, RNAi, and aptamers. 
riBozymes
Ribozymes are small, catalytically ac-
tive RNA molecules, the most well studied
being the hammerhead and the hairpin ri-
bozymes. The hammerhead ribozyme is one
of the smallest ribozymes and is composed
of 30 nucleotides with a conserved core and
three  stems  [3].  Natural  hammerhead  ri-
bozymes are self-cleaving molecules. How-
ever, these ribozymes can be engineered for
trans cleavage.  These  trans-cleaving  ri-
bozymes are composed of a conserved cat-
alytic domain, a structural domain, and a
target binding domain that provides the se-
quence specificity [4]. The only requirement
for the target domain is a 3-nucleotide con-
sensus sequence, thus allowing the flexibil-
ity to target a wide range of genes [4]. The
hairpin ribozyme is slightly larger than the
hammerhead  (50-60  nucleotides),  yet
cleaves substrates at more physiologically
relevant Mg2+ concentrations than the ham-
merhead [5]. Hairpin ribozymes are derived
from  the  minus  strand  of  the  tobacco
ringspot virus satellite RNA. Like the ham-
merhead ribozyme, hairpin ribozymes are
naturally self-cleaving but can be engineered
to cleave specific sequences by mutation of
the substrate recognition sequences flanking
the cleavage site sequence [5]. Trans-cleav-
ing ribozymes are of great therapeutic inter-
est as they can cleave multiple copies of
substrate  in  a  sequence-specific  manner,
thus removing genes of interest from the
genome.
The first clinical study to use ribozymes
to target a disease was conducted in HIV
positive patients in 1996 [6]. Hairpin ri-
bozymes were developed to target HIV U5
[7] and pol [8] and contain the stem loop II
sequence of HIV-Rev [9], thus serving as
both a ribozyme and a RNA decoy. These
constructs protected Jurkat T cell line and
PBMC from HIV infection with both labo-
ratory strains and clinical isolates [10,11].
Given the in vitro success of ribozyme ther-
apy, a clinical trial was launched to test the
safety and feasibility of a ribozyme-based
approach for HIV therapy [6]. PBMCs were
transduced ex vivo with a retroviral vector
pMJT expressing two hairpin ribozymes di-
rected against HIV U5 and pol and reinfused
into three HIV-positive subjects. Achieving
high transduction efficiency and reconstitu-
tion with these cells in vivo proved to be
challenging despite the promising in vitro
data. Vector was detected in only one patient
post-infusion, and no detection of the MLV-
driven pol riboyzme was achieved [6,12].
However, in this patient, the U5 ribozyme
driven by tRNAVal promoter was detected at
5 and 7 months post infusion, suggesting
that this promoter is better suited for in vivo
ribozyme expression. Despite low efficacy
of vector, this study marked the first clinical
trial  using  ribozymes  and  demonstrated
safety of ribozyme transduction into PBMC.
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bozyme delivery to CD34+ cells, murine
retroviral vectors were created to deliver
hammerhead ribozymes targeting HIV tat
and rev driven from the vector LTR [13].
These vectors effectively transduced CD34+
cells and showed a 1,000-fold inhibition of
HIV replication in vitro [14]. Two phase I
clinical trials were initiated utilizing these
vectors for ex vivo transduction of CD34+
cells in HIV positive patients showing no
symptoms or HIV positive lymphoma pa-
tients [15,16]. For the first study, no mye-
loablation was performed and presence of
vector was detected in only three of five pa-
tients, persisting in one patient for up to 6
months [15,16]. However, with myeloabla-
tion in a bone marrow transplant setting,
four of five patients showed high levels of
marking  initially  and  persistent  marking
throughout 1 year. A higher proportion of
PBMC were marked with vector carrying
the two ribozymes than the control vector,
suggesting a selective advantage was con-
ferred to these cells, and RNA expression
was detected in PBMC of these four pa-
tients. While these results are promising, the
levels of expression sharply declined, be-
coming undetectable after 1 year. This pro-
vides evidence that while transduction of
CD34+ cells with ribozymes is a feasible ap-
proach, improvements in transduction effi-
ciency must first be established.  
Johnson and Johnson Research also has
developed a ribozyme targeting HIV tat and
has now tested this therapy in the first phase
II cell-delivered clinical trial for HIV [17]. A
hammerhead ribozyme (Rz2) targeting the
overlapping vpr and tat reading frames of
HIV-1 was developed and tested in T cell
lines, primary T cells, and macrophages [18-
20]. Rz2 demonstrated high levels of inhibi-
tion of replication of laboratory strains and
AZT-  and  nevirapine-resistant  HIV.  No
emergence of escape mutants was observed,
and non-cleaving ribozymes showed far less
inhibition that catalytically active ribozyme
[19]. Retroviral transduction of CD34+ cells
with  Rz2  showed  high  transduction  effi-
ciency and had no deleterious effects on dif-
ferentiation of CD34+ in SCID-hu mice [21].
This vector was clinically tested in two con-
comitant phase I trials transducing either
CD4+  T  cells  [22,23]  or  CD34+  cells
[21,24]. To test transduction efficiency in
CD4+ T cells, four pairs of HIV discordant
identical twins were enrolled in a phase I
trial. HIV negative twins served as donors,
and CD4+ cells were isolated, transduced
with either Rz2 or control vector (LNL6), ex-
panded, and infused in HIV positive recipi-
ent twin [22,23]. In all patients, marking and
expression of ribozyme was observed at all
time points through at least 2 years and again
in the three patients that returned for a 6-year
time point [23]. Sequencing of quasispecies
isolated from these patients showed that no
mutations had occurred within the cleavage
site [23]. This study showed that expression
of Rz2 is highly stable in CD4+ lymphocytes
and transduction of these cells has no delete-
rious effects on survival.
Similar results were seen when CD34+
cells were transduced with Rz2 and autolo-
gously reinfused [21,24]. Ten HIV-positive
patients were recruited for this study. Trans-
duction efficiencies for the first three pa-
tients were low (< 1 percent to 4 percent)
and marking was seen up to 12 months [24].
The next seven patients were transduced in
the presence of CH296 fibronectin, increas-
ing transduction efficiencies to 32 percent.
Transgenes were detected in all patients at
multiple time points during the follow-up
with  the  latest  positive  detection  at  36
months. CD4+ T cell counts increased over
the 3-year period and viral load decreased
by an average 2.25 logs in six patients. As
with the CD4+ lymphocyte transduction, no
mutations in the catalytic target site were
seen.  Results  from  this  phase  1  trial
prompted a phase 2, multicenter, double-
blind, placebo-controlled clinical trial to as-
sess  feasibility  and  safety  of  this  gene
therapy approach [25]. Seventy-four early-
stage HIV-positive patients were divided
into OZ1 (formerly Rz2) or placebo infused
CD34+ cells. All patients’ viral load was
suppressed by HAART, and two HAART
treatment interruptions were conducted on
weeks 24 to 28 and again at weeks 40 to 48.
The second treatment interruption was al-
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study, week 100, as long as the patient met
study parameters. Initially, marking was ob-
served in 94 percent of OZ1-infused patients
but declined by week 100 to 7 percent. By
week  100,  12  participants  remained  on
HAART  treatment  interruption  and  OZ1
RNA was detected in five of these subjects.
The mean plasma viral loads for the OZ1-
treated group were lower, yet not signifi-
cantly. However, in a subset of patients that
continued to express OZ1 RNA, a statisti-
cally significant decrease in viral load was
observed. While the low engraftment levels
and short persistence of the ribozyme are
disheartening, it is encouraging that efficacy
was seen in patients that did express OZ1
RNA and that infusion was well tolerated,
causing no apparent adverse events.
The clinical trials described so far have
focused on the use of ribozymes alone. How-
ever, the combination of ribozymes with ad-
ditional  RNA-based  strategies  may  help
prevent escape mutants and attack the virus
with multiple approaches. Recently, this con-
cept was tested in a phase I clinical trial com-
bining a CCR5 targeting ribozyme (R5RZ),
a TAR decoy, and shRNA targeting a tat/rev
exon (shI) [26]. In vitro studies first focused
on characterizing the individual components
of this vector [27-29] and then the double
vector with TAR decoy and R5RZ. Both T
cell lines and CD34+ cells were protected
against HIV infection and provided a selec-
tive  advantage  over  untransduced  cells
[29,30]. Combination of the TAR decoy, the
R5RZ, and shI showed a 4-log reduction in
HIV titers and provided stable transduction
of CD34+ without affecting characteristics
of differentiated macrophages [30]. These
cells also differentiated similar to controls
when used to reconstitute SCID-hu mice
[31]. Clinical trials were initiated with four
AIDS  lymphoma  patients  receiving  bone
marrow transplant of both vector transduced
and untransduced CD34+ cells [26]. Patients
remained on HAART throughout the dura-
tion of the study and had undetectable viral
loads. Encouragingly, all patients remained
in remission from leukemia and had marking
of PBMC including T cells, monocytes, and
B cells up to 24 months following infusion.
A second phase 1 trial is currently recruiting
patients that have failed anti-retroviral ther-
apy for a multi-dose study with infusion of
transduced T cells [32].
While none of these trials alone have
proved therapeutic effect, taken together they
provide a proof-of-principle that ribozyme
therapy could be an efficacious approach to
the treatment of HIV. Improvements in trans-
duction efficiencies of CD34+ and CD4+
cells paired with increased engraftment and
expansion of these cells in vivo could lead to
greater therapeutic effects.
rnAi-BAsed strAteGies
RNA Interference (RNAi) utilizes short
RNAs to mediate degradation of mRNA in a
sequence specific manner. RNAi can be de-
livered either as a synthetic 21 basepair dou-
ble-stranded RNA (siRNA) or as a stably
expressed  precursor  short  hairpin  RNA
(shRNA).  Additionally,  long  antisense
oligonucleotides can be designed to bind to
mRNA and trigger degradation of mRNA
through a RNase H dependent pathway or
block ribosome binding, inhibiting gene ex-
pression.  During the HIV lifecycle, HIV
RNA is exposed to the cytoplasm both ini-
tially upon viral uncoating and once tran-
scribed  from  proviral  DNA. This  allows
ample interaction of potentially therapeutic
RNAi-based therapies with viral RNA and
should therefore provide an ideal situation
to combat HIV.
To our knowledge, to-date clinical stud-
ies utilizing RNAi to combat HIV infection
have relied on antisense strategies with the
exception of the tat/rev shRNA, R5RZ, Tar
decoy described above [26]. The usage of
these long antisense constructs can help pre-
vent escape mutants as large portions of the
targeted gene would need to be deleted to
allow escape causing severe decreases in fit-
ness [33]. Additionally, antisense that is di-
rected  against  genes  not  present  in  the
targeting vector does not compromise vec-
tor gene expression and allows for high titer
vector production. Therefore, it is not sur-
prising that antisense HIV env has been an
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sense env VRX496 was encoded in a condi-
tionally  replicating  VSV-G  pseudotyped
lentiviral vector that showed in vitro reduc-
tion of HIV titers up to 4 logs [35,36]. Phase
I trials using VRX496 transduced autolo-
gous CD4+ T cell infusion in chronic HIV
patients showed high initial engraftment of
marked  cells  with  up  to  105 copies/106
PBMC [37]. Though this marking rapidly
declined with only two of five patients hav-
ing detectable vector after 2 years, three of
five patients showed reduced HIV titers and
four of the five showed improvement in
CD4+ cell count. Analysis of integration
sites showed no preferential integration. Ad-
ditionally, no replication-competent virus
was detected, and only transient mobiliza-
tion of the vector through day 60 was ob-
served. VIRxSYS Corporation has initiated
further clinical testing of this vector, includ-
ing two phase II trials to further examine
dosing and one phase I/II trial withdrawing
patients from HAART [38]. While data has
not yet been published, 18 patients have cur-
rently been enrolled for this phaseI/II trial
and results to date are said to be encouraging
[38].
In addition to antisense env, antisense
TAR in combination with trans-dominant
Rev has also been examined in a clinical set-
ting [39]. Ten pairs of HIV discordant iden-
tical twins were recruited, and CD4+ cells
from the seronegative twin were transduced
and infused into the seropositive twin. CD4+
cells were transduced with a single MLV or
GALV vector carrying both the dominant
negative Rev and the antisense TAR, with
vectors carrying dominant Rev alone, or
with control vectors carrying no anti-HIV
genes. Marking following infusion was be-
tween  500  and  1,000  marked  cells/106
PBMC and declined during the first two
months to ~100 marked cells/106 PBMC.
However, though marking decreased over
time, the ratio of cells carrying therapeutic
vector to control vector shifted 1- to 3-fold,
suggesting that a selective advantage was
seen in cells carrying anti-HIV therapy. This
shift was even more pronounced when one
subject was removed from HAART causing
viral rebound, and then infused. Here, the
ratio of treatment to control marked cells
reached a 100-fold shift, and viral load de-
creased to half the level at time of infusion.
Enzo Biochem Inc. has also developed
and clinically tested its own antisense vector
Stealth Vector HGTV43 encoding U1/anti-
sense TAR and antisense directed at two
separate  regions  of  the  tat/rev region
[40,41]. In a phase I trial with five HIV
seropositive subjects, ex vivo transduction of
CD34+ and autologous infusion led to mark-
ing of CD34+ and CD4+ T cells up to 72
months following infusion. All subjects tol-
erated the treatment with no serious adverse
events, and Enzo has now begun a phase I/II
trial to optimize transduction rates [40].
While studies using shRNA and siRNA
alone have not yet progressed to clinical tri-
als, a number of promising pre-clinical stud-
ies have provided the proof of principle for
the use of this technology as an anti-HIV
therapeutic. Pre-clinical targets of siRNA
treatment have included both host factors
such as CCR5 [42-44], viral genes such as
nef [45], or a combination of viral and host
factors [46]. While the current clinical trials
rely on ex vivo transduction of CD34+ cells
or CD4+ cells, preclinical studies using tar-
geted delivery of siRNA or shRNA to HIV
susceptible cells give hope for an easy to ad-
minister RNAi-based treatment [43,44,46].
Given the recent success of targeted deliv-
ery of siRNA in humans for the treatment of
melanoma, it will be exciting to see the
growth of these strategies in the HIV field
[47].
rnA APtAmers
Aptamers are single-stranded RNA or
DNA molecules that can bind proteins with
high affinity serving as a decoy. These mol-
ecules, normally 15 to 40 bases long, can be
used as decoys to bind viral proteins or as
vehicles for targeted delivery of siRNAs.
These molecules are being explored for their
use in vivo as they are non-toxic and non-
immunogenic [48]. A recent clinical study
discussed above examined the efficacy of a
triple construct lentiviral vector expressing a
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only one clinical trial has used aptamers
alone and reported discouraging results [49].
For this study, overexpression of the rev-re-
sponsive element (RRE) was driven off the
LTR of a retroviral vector [14,50]. In cul-
ture, this decoy inhibited HIV replication up
to 1,000-fold without affecting differentia-
tion of CD34+ cells. However, when four
HIV+  children  were  autologously  trans-
planted with CD34+ cells transduced by
MoMuLV RRE decoy vector, marking was
only detected in two subjects and disap-
peared as quickly as 7 days post infusion
[49]. Transduction efficiencies of CD34+
cells were between 7 percent and 30 percent
and persistence of the control vector LN was
seen through 330 days. The low engraftment
of these cells could be due to the high rate of
quiescent CD34+ cells that are not trans-
ducible by MoMuLV and with the improve-
ments seen by using lentiviral based vectors
for transduction of quiescent cells, an im-
provement may be possible.
Preclinically, aptamers to gp120 have
been used for their dual function in targeting
delivery and inhibiting viral binding [51,52].
Aptamers to gp120 were fused to siRNA tar-
geting tat/rev and delivered specifically to
CHO-gp160 and HIV-infected CEM T cells
without  triggering  an  interferon  response
[51]. Recently, improvements upon the fused
aptamer-siRNA were reported [53]. Here, a
GC-rich bridge allows a stable interaction of
the aptamer and siRNA, but allows inter-
change of the siRNA, facilitating the silenc-
ing  of  mutants.  These  aptamers  alone
showed HIV inhibition that was further pro-
nounced when “stuck” to anti-tat/rev, anti-
transportin 3, and anti-CD4 siRNA. Efficacy
of  these  aptamer  chimeras  were  recently
tested in the humanized mouse model [52].
Rag2-/--/- mice  were  reconstituted  with
human CD34+ cells and infected with HIV-
1 NL4.3 virus. Starting 3 weeks after viral
infection, mice were injected weekly with
gp120-siRNA chimeras. Decreases in viral
load up to three logs of reduction and pro-
tection of CD4+ T cells have been reported.
The ability of this chimeric aptamer to show
efficacy in a therapeutic setting extends hope
for a potential treatment for patients failing
HAART therapy.  
conclusions
The studies presented in this review
provide an overview of the clinical trials that
have utilized RNA-based gene therapy for
the treatment or prevention of HIV. While
none of these studies to date have shown ef-
ficacy against HIV, they provide proof of
principle that the use of RNA-based thera-
pies is feasible and safe in vivo. As advances
in vector technology allow for higher levels
of transduction of CD34+ and CD4+ cells,
the potential efficacy of these therapies can
be greatly improved. Many of these studies
also rely on a selective advantage for the ex-
pansion of transduced cells. This is difficult
to achieve in subjects with well-controlled
HIV levels remaining on HAART. As these
therapies progress along the pipeline, it will
be exciting to compare the selective advan-
tages seen in vitro to those actually achieved
in vivo. Additional technological advances
in the field have focused on targeted deliv-
ery to eliminate the need for expensive and
time consuming ex vivo transduction. As
preclinical studies continue to show the ef-
ficacy of these approaches, targeted delivery
to T cells may be an achievable milestone in
the clinic.   
reFerences
1. World Health Organization: Global Epidemic
Data and Statistics 2010 [Internet]. Available from:
http://www.who.int/hiv/data/global_data/en/index
.html.
2. Scherer L, Rossi J, Weinberg M. Progress and
prospects: RNA-based therapies for treatment
of HIV infection. Gene Ther. 2007;14(14):1057-
64. 
3. Birikh K, Heaton P, Eckstein F. The structure,
function and application of the hammerhead
ribozyme. Eur J Biochem. 1997;245(1):1-16.
4. Citti L, Rainaldi G. Synthetic hammerhead
ribozymes as therapeutic tools to control dis-
ease genes. Curr Gene Ther. 2005;5(1):11-24.
5. Duarte E, Leavitt M, Yamada O, Yu M. Hair-
pin ribozyme gene therapy for AIDS. Meth-
ods Mol Biol. 1997;74:459-68.
6. Wong-Staal F, Poeschla E, Looney D. A con-
trolled, Phase 1 clinical trial to evaluate the
safety and effects in HIV-1 infected humans
of autologous lymphocytes transduced with
307 Zeller and Kumar: RNA-based gene therapy for HIV treatment, preventiona ribozyme that cleaves HIV-1 RNA. Hum
Gene Ther. 1998;9(16):2407-25.
7. Ojwang J, Hampel A, Looney D, Wong-Staal
F, Rappaport J. Inhibition of human immun-
odeficiency virus type 1 expression by a hair-
pin  ribozyme.  Proc  Natl  Acad  Sci  USA.
1992;89(22):10802-6. 
8. Yu M, Poeschla E, Yamada O, Degrandis P,
Leavitt M, Heusch M, et al. In vitro and in
vivo characterization of a second functional
hairpin ribozyme against HIV-1. Virology.
1995;206(1):381-6.
9. Yamada O, Kraus G, Luznik L, Yu M, Wong-
Staal F. A chimeric human immunodeficiency
virus type 1 (HIV-1) minimal Rev response el-
ement-ribozyme molecule exhibits dual antivi-
ral function and inhibits cell-cell transmission
of HIV-1. J Virol. 1996;70(3):1596-601.
10. Gervaix A, Li X, Kraus G, Wong-Staal F.
Multigene antiviral vectors inhibit diverse
human  immunodeficiency  virus  type  1
clades. J Virol. 1997;71(4):3048-53.
11. Leavitt  M,  Yu  M,  Yamada  O,  Kraus  G,
Looney D, Poeschla E, et al. Transfer of an
anti-HIV-1  ribozyme  gene  into  primary
human  lymphocytes.  Hum  Gene  Ther.
1994;5(9):1115-20.
12. Kr￼ger M, Beger C, Wong-Staal F. Use of ri-
bozymes to inhibit gene expression. Methods
Enzymol. 1999;306:207-25.
13. Zhou C, Bahner I, Larson G, Zaia J, Rossi J,
Kohn E. Inhibition of HIV-1 in human T-lym-
phocytes by retrovirally transduced anti-tat
and  rev  hammerhead  ribozymes.  Gene.
1994;149(1):33-9.
14. Bauer G, Valdez P, Kearns K, Bahner I, Wen
S, Zaia J, et al. Inhibition of human immun-
odeficiency virus-1 (HIV-1) replication after
transduction of granulocyte colony-stimulat-
ing factor-mobilized CD34+ cells from HIV-
1-infected  donors  using  retroviral  vectors
containing  anti-HIV-1  genes.  Blood.
1997;89(7):2259-67.
15. Michienzi A, Castanotto D, Lee N, Li S, Zaia
J, Rossi J. RNA-mediated inhibition of HIV
in a gene therapy setting. Ann NY Acad Sci.
2003;1002:63-71.
16. Michienzi A, Castanotto D, Lee N, Li S, Zaia
JA, Rossi JJ. Novel ribozyme, RNA decoy,
and siRNA approaches to inhibition of HIV
in a gene therapy setting. Clinical and Ap-
plied  Immunology  Reviews.  2003;3(4-
5):223-33.
17. Burnett J, Rossi J. Stem cells, ribozymes and
HIV. Gene Ther. 2009;16(10):1178-9.
18. Sun L, Pyati J, Smythe J, Wang L, Macpher-
son J, Gerlach W, et al. Resistance to human
immunodeficiency virus type 1 infection con-
ferred by transduction of human peripheral
blood lymphocytes with ribozyme, antisense,
or polymeric trans-activation response ele-
ment constructs. Proc Natl Acad Sci USA.
1995;92(16):7272-6.
19. Sun L, Wang L, Gerlach W, Symonds G. Tar-
get  sequence-specific  inhibition  of  HIV-1
replication by ribozymes directed to tat RNA.
Nucleic Acids Res. 1995;23(15):2909-13.
20. Wang L, Witherington C, King A, Gerlach W,
Carr A, Penny R, et al. Preclinical characteri-
zation of an anti-tat ribozyme for therapeutic
application. Hum Gene Ther. 1998;9(9):1283-
91.
21. Amado R, Mitsuyasu R, Symonds G, Rosen-
blatt J, Zack J, Sun L, et al. A phase I trial of
autologous CD34+ hematopoietic progenitor
cells transduced with an anti-HIV ribozyme.
Hum Gene Ther. 1999;10(13):2255-70.
22. Cooper D, Penny R, Symonds G, Carr A,
Gerlach W, Sun L, et al. A marker study of
therapeutically transduced CD4+ peripheral
blood lymphocytes in HIV discordant identi-
cal twins. Hum Gene Ther. 1999;10(8):1401-
21.
23. Macpherson J, Boyd M, Arndt A, Todd A, Fan-
ning G, Ely J, et al. Long-term survival and
concomitant  gene  expression  of  ribozyme-
transduced CD4+ T-lymphocytes in HIV-in-
fected patients. J Gene Med. 2005;7(5):552-64.
24. Amado R, Mitsuyasu R, Rosenblatt J, Ngok
F, Bakker A, Cole S, et al. Anti-human im-
munodeficiency virus hematopoietic progen-
itor  cell-delivered  ribozyme  in  a  phase  I
study: myeloid and lymphoid reconstitution
in human immunodeficiency virus type-1-in-
fected  patients.  Hum  Gene  Ther.
2004;15(3):251-62.
25. Mitsuyasu R, Merigan T, Carr A, Zack J, Win-
ters M, Workman C, et al. Phase 2 gene therapy
trial of an anti-HIV ribozyme in autologous
CD34+ cells. Nat Med. 2009;15(3):285-92.
26. DiGiusto D, Krishnan A, Li L, Li H, Li S,
Rao A, et al. RNA-based gene therapy for
HIV with lentiviral vector-modified CD34(+)
cells in patients undergoing transplantation
for AIDS-related lymphoma. Sci Transl Med.
2010;2(36):36ra43.
27. Michienzi A, Li S, Zaia J, Rossi J. A nucleo-
lar TAR decoy inhibitor of HIV-1 replication.
Proc Natl Acad Sci USA. 2002;99(22):14047-
52.
28. Cagnon L, Rossi J. Downregulation of the
CCR5 beta-chemokine receptor and inhibi-
tion of HIV-1 infection by stable VA1-ri-
bozyme  chimeric  transcripts.  Antisense
Nucleic Acid Drug Dev. 2000;10(4):251-61.
29. Li M, Bauer G, Michienzi A, Yee J, Lee N,
Kim J, et al. Inhibition of HIV-1 infection by
lentiviral vectors expressing Pol III-promoted
anti-HIV RNAs. Mol Ther. 2003;8(2):196-
206.
30. Li M, Kim J, Li S, Zaia J, Yee J, Anderson J,
et al. Long-term inhibition of HIV-1 infection
in primary hematopoietic cells by lentiviral
vector delivery of a triple combination of
anti-HIV shRNA, anti-CCR5 ribozyme, and
a nucleolar-localizing TAR decoy. Mol Ther.
2005;12(5):900-9.
31. Anderson J, Li M, Palmer B, Remling L, Li
S, Yam P, et al. Safety and efficacy of a
lentiviral vector containing three anti-HIV
308 Zeller and Kumar: RNA-based gene therapy for HIV treatment, preventiongenes—CCR5 ribozyme, tat-rev siRNA, and
TAR decoy—in SCID-hu mouse-derived T
cells. Mol Ther. 2007;15(6):1182-8.
32. ClinicalTrials.gov: Gene Transfers for HIV Using




33. Lu X, Yu Q, Binder G, Chen Z, Slepushkina
T, Rossi J, et al. Antisense-mediated inhibi-
tion of human immunodeficiency virus (HIV)
replication by use of an HIV type 1-based
vector results in severely attenuated mutants
incapable of developing resistance. J Virol.
2004;78(13):7079-88. 
34. Mautino M, Morgan R. Potent inhibition of
human immunodeficiency virus type 1 repli-
cation by conditionally replicating human
immunodeficiency virus-based lentiviral vec-
tors expressing envelope antisense mRNA.
Hum Gene Ther. 2000;11(14):2025-37.
35. Humeau L, Binder G, Lu X, Slepushkin V,
Merling  R,  Echeagaray  P,  et  al.  Efficient
lentiviral vector-mediated control of HIV-1
replication in CD4 lymphocytes from diverse
HIV+ infected patients grouped according to
CD4  count  and  viral  load.  Mol  Ther.
2004;9(6):902-13.
36. Lu X, Humeau L, Slepushkin V, Binder G, Yu
Q, Slepushkina T, et al. Safe two-plasmid
production for the first clinical lentivirus vec-
tor that achieves >99% transduction in pri-
mary cells using a one-step protocol. J Gene
Med. 2004;6(9):963-73.
37. Levine B, Humeau L, Boyer J, MacGregor R,
Rebello T, Lu X, et al. Gene transfer in hu-
mans  using  a  conditionally  replicating
lentiviral vector. Proc Natl Acad Sci USA.
2006;103(46):17372-7.
38.VIRxSYS.com:  HIV  RNA  Therapy
2009  [Internet].  Available  from:
http://www.virxsys.com/pages/human-
therapies/hiv-rna-therapy.php.
39. Morgan R, Walker R, Carter C, Natarajan V,
Tavel J, Bechtel C, et al. Preferential survival
of  CD4+ T  lymphocytes  engineered  with
anti-human immunodeficiency virus (HIV)
genes  in  HIV-infected  individuals.  Hum
Gene Ther. 2005;16(9):1065-74.
40. Enzo.com. Research and Focus [Internet].
Available from: www.enzo.com/therapeutics.
41. Liu D, Conant M, Cowan M, Laurence J,
Eden C, Dunn E, et al. Engraftment and de-
velopment of HGTV43-transduced CD34+
PBSC in HIV-1 seropositive individuals. In-
ternational Conference on AIDS; 2002, Jul 7-
12; Barcelona, Spain.
42. An D, Donahue R, Kamata M, Poon B, Met-
zger M, Mao S, et al. Stable reduction of
CCR5 by RNAi through hematopoietic stem
cell transplant in non-human primates. Proc
Natl Acad Sci USA. 2007;104(32):13110-5.
43. Anderson J, Walker J, Nolta J, Bauer G. Spe-
cific transduction of HIV-susceptible cells for
CCR5 knockdown and resistance to HIV in-
fection: a novel method for targeted gene
therapy and intracellular immunization. J Ac-
quir Immune Defic Syndr. 2009;52(2):152-
61.
44. Kim S, Peer D, Kumar P, Subramanya S, Wu
H, Asthana D, et al. RNAi-mediated CCR5
silencing by LFA-1-targeted nanoparticles
prevents HIV infection in BLT mice. Mol
Ther. 2010;18(2):370-6.
45. ter  Brake  O,  Legrand  N,  von  Eije  K,
Centlivre M, Spits H, Weijer K, et al. Evalu-
ation of safety and efficacy of RNAi against
HIV-1 in the human immune system (Rag-2(-
/-)gammac(-/-)) mouse model. Gene Ther.
2009;16(1):148-53.
46. Kumar P, Ban H, Kim S, Wu H, Pearson T,
Greiner D, et al. T cell-specific siRNA deliv-
ery suppresses HIV-1 infection in humanized
mice. Cell. 2008;134(4):577-86.
47. Davis M, Zuckerman J, Choi C, Seligson D,
Tolcher A, Alabi C, et al. Evidence of RNAi
in humans from systemically administered
siRNA via targeted nanoparticles. Nature.
2010;464(7291):1067-70.
48. Syed M, Pervaiz S. Advances in Aptamers.
Oligonucleotides. 2010;20(5):215-24.
49. Kohn D, Bauer G, Rice C, Rothschild J, Car-
bonaro D, Valdez P, et al. A clinical trial of
retroviral-mediated transfer of a rev-respon-
sive element decoy gene into CD34(+) cells
from the bone marrow of human immunode-
ficiency  virus-1-infected  children.  Blood.
1999;94(1):368-71.
50. Bahner I, Kearns K, Hao Q, Smogorzewska
E, Kohn D. Transduction of human CD34+
hematopoietic progenitor cells by a retroviral
vector  expressing  an  RRE  decoy  inhibits
human immunodeficiency virus type 1 repli-
cation in myelomonocytic cells produced in
long-term culture. J Virol. 1996;70(7):4352-
60.
51. Zhou J, Li H, Li S, Zaia J, Rossi J. Novel dual
inhibitory function aptamer-siRNA delivery
system  for  HIV-1  therapy.  Mol  Ther.
2008;16(8):1481-9.
52. Zhou J, Rossi J. Aptamer-targeted cell-spe-
cific RNA interference. Silence. 2010;1(1):4.
53. Zhou J, Swiderski P, Li H, Zhang J, Neff C,
Akkina R, et al. Selection, characterization
and application of new RNA HIV gp 120 ap-
tamers for facile delivery of Dicer substrate
siRNAs  into  HIV  infected  cells.  Nucleic
Acids Res. 2009;37(9):3094-109.
309 Zeller and Kumar: RNA-based gene therapy for HIV treatment, prevention